Business Context and Reporting Period
This Form 8-K was filed by Matinas Biopharma Holdings, Inc. on March 22, 2018. The company is an emerging growth company incorporated in Delaware. The report primarily addresses the execution of a new employment agreement with Jerome D. Jabbour, the Chief Executive Officer.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific compensation package for the CEO:
- Signing Bonus: $84,000
- Base Salary: $350,000 per year
- Target Annual Bonus: 50% of base salary
- Equity Grant: Option to purchase 1,000,000 shares
Material Changes
The material change reported is the formalization of the CEO's compensation structure effective March 22, 2018. The agreement includes performance-based salary increases contingent on equity financing milestones:
- Salary increases to $400,000 if $5,000,000 in gross proceeds are raised prior to March 15, 2019.
- Salary increases to $425,000 if $15,000,000 in gross proceeds are raised prior to March 15, 2019.
Outlook, Risks, and Contingencies
The filing outlines significant contingent liabilities related to executive severance:
- Standard Termination: If terminated without cause or if the CEO resigns with good reason (absent a change of control), the company must pay up to 12 months of base salary plus 12 months of COBRA benefits. Additionally, 50% of outstanding options vest immediately.
- Change of Control Termination: If terminated without cause or resignation with good reason occurs within 24 months of a change of control, the company must pay up to 24 months of base salary plus the target annual bonus and 18 months of COBRA benefits. All options vest in full.
The salary increase triggers indicate a strategic focus on securing equity financing in the near term.
Investor Verification Checklist
- Verify the company's current cash position to assess the ability to fund the $84,000 signing bonus and ongoing salary obligations.
- Monitor upcoming equity financing announcements to determine if the $5 million or $15 million thresholds are met, triggering salary increases.
- Review the total outstanding option pool to understand the dilution impact of the 1,000,000 share grant and potential future grants.
- Assess the potential cash outflow for severance packages in the event of a change of control or executive departure.